Steven Cohen Allogene Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

  • $36.6 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$2.28 - $3.5 $1.55 Million - $2.38 Million
679,468 New
679,468 $2.18 Million
Q2 2023

Aug 14, 2023
BUY
$4.53 - $6.74 $539 - $802
119 Added 5.67%
2,217 $11,000
Q1 2023

May 15, 2023
BUY
$4.92 - $8.21 $10,322 - $17,224
2,098 New
2,098 $10,000
Q3 2022

Nov 14, 2022
BUY
$10.32 - $17.28 $3.03 Million - $5.07 Million
293,200 New
293,200 $3.17 Million

Others Institutions Holding ALLO

# of Institutions
162
Shares Held
134M
Call Options Held
59.4K
Put Options Held
113K
View Full List

About Allogene Therapeutics, Inc.

ALLO Quotes by TradingView
  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email